Primary neuroprotection: the Holy Grail of multiple sclerosis therapy

Neurology. 2010 Mar 30;74(13):1018-9. doi: 10.1212/WNL.0b013e3181d6b165. Epub 2010 Mar 3.
No abstract available

Publication types

  • Comment
  • Editorial
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Brain / drug effects
  • Brain / pathology
  • Clinical Trials, Phase II as Topic
  • Dose-Response Relationship, Drug
  • Humans
  • Multiple Sclerosis / drug therapy*
  • Multiple Sclerosis / immunology
  • Multiple Sclerosis / pathology
  • Multiple Sclerosis, Chronic Progressive / drug therapy
  • Multiple Sclerosis, Chronic Progressive / immunology
  • Multiple Sclerosis, Chronic Progressive / pathology
  • Neuroprotective Agents / administration & dosage
  • Neuroprotective Agents / therapeutic use*
  • Phosphodiesterase Inhibitors / administration & dosage
  • Phosphodiesterase Inhibitors / therapeutic use
  • Pyridines / administration & dosage
  • Pyridines / therapeutic use*
  • Severity of Illness Index
  • Treatment Outcome

Substances

  • Neuroprotective Agents
  • Phosphodiesterase Inhibitors
  • Pyridines
  • ibudilast